RPG Life Sciences Limited announced the unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27), both on standalone and consolidated basis, following a board meeting held on July 28, 2026. The meeting commenced at 3:00 PM and concluded at 6:30 PM.
Standalone Financial Results (₹ in lakhs)
| Particulars | Q1 FY27 (Unaudited) | Q4 FY26 (Audited) | Q1 FY26 (Unaudited) | FY26 (Audited) |
| Revenue from Operations | 19,695 | 17,689 | 16,892 | 70,752 |
| Other Income | 416 | 1,236 | 523 | 2,554 |
| Total Income | 19,985 | 18,925 | 17,415 | 73,306 |
| Total Expenses | 15,864 | 15,015 | 13,872 | 58,276 |
| Profit Before Exceptional Items & Tax | 4,121 | 3,910 | 3,543 | 15,030 |
| Exceptional Items | - | 110 | - | 390 |
| Profit Before Tax | 4,121 | 4,020 | 3,543 | 15,420 |
| Tax Expense | 1,064 | 1,030 | 914 | 3,903 |
| Profit After Tax | 3,057 | 2,990 | 2,629 | 11,517 |
| Other Comprehensive Income | (15) | 8 | (1) | (64) |
| Total Comprehensive Income | 3,042 | 2,998 | 2,628 | 11,453 |
| Paid-up Equity Share Capital | 1,323 | 1,323 | 1,323 | 1,323 |
| Basic EPS (₹) | 18.49 | 18.08 | 15.90 | 69.64 |
| Diluted EPS (₹) | 18.49 | 18.08 | 15.90 | 69.64 |
Consolidated Financial Results (₹ in lakhs)
| Particulars | Q1 FY27 (Unaudited) | Q4 FY26 (Audited) | Q1 FY26 (Unaudited) | FY26 (Audited) |
| Revenue from Operations | 19,695 | 17,689 | 16,892 | 70,752 |
| Other Income | 470 | 1,240 | 523 | 2,558 |
| Total Income | 20,039 | 18,929 | 17,415 | 73,310 |
| Total Expenses | 15,893 | 15,019 | 13,872 | 58,280 |
| Profit Before Exceptional Items & Tax | 4,146 | 3,910 | 3,543 | 15,030 |
| Exceptional Items | - | 110 | - | 390 |
| Profit Before Tax | 4,146 | 4,020 | 3,543 | 15,420 |
| Tax Expense | 1,070 | 1,030 | 914 | 3,903 |
| Profit After Tax | 3,076 | 2,990 | 2,629 | 11,517 |
| Other Comprehensive Income | (15) | 8 | (1) | (64) |
| Total Comprehensive Income | 3,061 | 2,998 | 2,628 | 11,453 |
| Paid-up Equity Share Capital | 1,323 | 1,323 | 1,323 | 1,323 |
| Basic EPS (₹) | 18.60 | 18.08 | 15.90 | 69.64 |
| Diluted EPS (₹) | 18.60 | 18.08 | 15.90 | 69.64 |
Exceptional Items Details
- Insurance Claim Settlement: During FY26, the company received full settlement of ₹247.5 lakhs for the insurance claim relating to a fire incident at its Navi Mumbai API plant in January 2025. This was recognized as exceptional income in the respective quarters when received. Additionally, ₹79.1 lakhs received for business interruption losses was recognized as Other Income in Q4 FY26.
- New Labour Codes Impact: The company recognized an exceptional expense of ₹116.9 lakhs towards the impact of New Labour Codes notified effective November 22, 2025, primarily due to change in wage definition.
- Intangible Asset Write-off: Exceptional items for Q4 FY26 and FY26 include write-off of ₹91.6 lakhs for an intangible asset under development based on management's impairment assessment.
Corporate Action
The Board of Directors, at its meeting on December 15, 2025, approved the transfer of the API division to its wholly-owned subsidiary RPG Active Pharma Limited (incorporated on December 24, 2025). The transaction is subject to receipt of all requisite consents and completion of customary conditions precedent.